Eli Lilly already has a couple of top GLP-1 drugs that help patients with diabetes (Mounjaro) and weight loss (Zepbound), but ...

Recursion Pharmaceuticals ( RXRX -5.13%) is not the most famous artificial intelligence (AI) stock on the market, but the ...

Trying to choose between ACH vs wire transfer? Compare fees, speed, and security to pick the best option for your financial ...

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothol ...

Wall Street's major averages plummeted on Friday after Israel and Iran traded missile strikes and stoked concerns of an ...

Dilok Klaisataporn Most major stock indexes across the globe ended the week lower, following US-China trade talks and renewed ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

The analyst is thus maintaining a cautious stance on the stock. Novo Nordisk A/S (NYSE:NVO) is a global healthcare company ...

Novo Nordisk A/S (NYSE:NVO) is one of the 17 stocks that Jim Cramer commented on. During the episode, Cramer said that he ...